Last reviewed · How we verify
Ablysinol (Ethanol)
Ablysinol, also known as ethanol, is a small molecule drug originally developed by B BRAUN and currently owned by Qol Medcl. It targets the GABA A receptor alpha-4/beta-2/delta, modulating its activity. Ablysinol is FDA-approved for use as an antiseptic preparation, with an 80% bioavailability. It is off-patent, meaning it is no longer protected by patents, and there are no generic manufacturers. As a result, its commercial status is limited.
At a glance
| Generic name | Ethanol |
|---|---|
| Also known as | Ethyl Alcohol, Ehtyol, Ethamolin, oral ethanol, oral placebo ethanol |
| Sponsor | Qol Medcl |
| Drug class | ethanol |
| Target | GABA A receptor alpha-4/beta-2/delta |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1946 |
Approved indications
- Antiseptic preparation
Common side effects
- Diarrhea
- Nausea
- Rash
- Headache
- Abdominal pain
- Vomiting
Serious adverse events
- Toxic epidermal necrolysis
- Acute generalized exanthematous pustulosis
- Drug rash with eosinophilia and systemic symptoms
- Hepatotoxicity
- Rhabdomyolysis
- Crystal nephropathy
- Crystalluria
- Renal impairment
- Immune Reconstitution Syndrome
- Redistribution of body fat
Drug interactions
- disulfiram
- methotrexate
- metronidazole
Key clinical trials
- Characterization Imaging Instruments in Alcoholics and Non-Alcoholics
- A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder (PHASE2)
- Effect of Alcohol Sclerotherapy on Pelvic Pain and Quality of Life in Women With Ovarian Endometriosis (NA)
- Tirzepatide in MetALD (PHASE2)
- NIAAA Natural History Protocol
- Hepatic Lipid Metabolism-Alcohol Use Disorder
- Assessment of Non-Invasive Testing in Major Liver-Related Outcomes
- Virtual Reality (VR) NATURE - Alcohol Use Disorder (AUD) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ablysinol CI brief — competitive landscape report
- Ablysinol updates RSS · CI watch RSS
- Qol Medcl portfolio CI